Transmedics Group Inc Drops 5.03% on Technical Indicator
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 02 Dec 25
Transmedics Group Inc's stock has declined by 5.03%, crossing down the 5-day SMA.
This movement reflects a technical signal that may indicate bearish sentiment among investors. The broader market, including the Nasdaq-100 and S&P 500, has shown gains, suggesting that the decline in TMDX is specific to the company.
Investors will be watching for any upcoming news or developments that could impact Transmedics Group Inc's performance in the near future.
Analyst Views on TMDX
Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is 147.80 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 140.990
Low
115.00
Averages
147.80
High
170.00
Current: 140.990
Low
115.00
Averages
147.80
High
170.00
About TMDX
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
